Table 2

Averaged antimicrobial resistance of the main Gram negative uropathogens for female and male patients
Antimicrobial group Antimicrobials E. coli P. mirabilis Klebsiella spp P. vulgaris P. aeruginosa Enterobacter spp Providencia spp
N % M F N % M F N % M F N % M F N % M F N % M F N % M F
Aminoglycosides Amikacin 12048 1.5 1.9 1.4 865 4.3 5.7 3.8 800 2.6 2.6 2.6 492 7.3 6.4 7.6 443 7.9 7.1 8.7 360 7.8 9.1 7.0 307 92.8 89.2 93.8
Gentamicin 12034 3.6 6.3* 3.1 868 5.4 7.1* 4.9 798 7.3 8.4 6.8 487 12.9 12.2 13.2 441 15.2 15.7 14.7 361 10.8 13 9.6 307 93.8 90.8 94.6
Isepamicin 10995 1.3 1.8 1.3 787 3.4 4.6 3.1 707 2.0 2.4 1.8 444 6.3 5.4 6.6 387 8.3 8.2 8.3 348 3.2 4.1 2.7 282 92.9 91.7 93.2
Netilmicin 11976 1.3 1.7 1.2 854 0.9 2.9* 0.3 792 2.5 2.7 2.5 484 5.8 7.3 5.3 443 14.4 15.6 13.4 358 8.7 14.5* 5.3 307 94.5 93.8 94.6
Tobramycin 11999 3.0 4.9* 2.6 860 4.1 7.3* 3.1 793 5.8 8.0* 4.9 494 12.6 14.4 11.9 443 16.5 17.0 16.0 358 14.5 23.1* 9.6 306 94.4 93.8 94.6
Carbapenems Imipenem 11846 0.2 0.4 0.1 846 1.3 2.9* 0.8 785 0.4 0.0 0.5 482 2.9 2.4 3.1 425 2.4 2.0 2.7 337 2.1 4.3* 0.9 308 1.3 3.2 0.8
Cephalosporins 1st G Cefazolin 11919 10.5 15.8* 9.4 862 22.2 31.1* 19.3 766 29.9 37.3* 26.9 484 94.8 97.6 93.8 152 98.0 97.3 98.7 346 96.0 97.6 95.0 311 95.5 92.4 96.3
Cephradine 11994 14.1 19.2* 13.0 862 22.3 30.8* 19.5 788 32.0 38.1 29.6 486 95.9 98.4 95.0 155 98.7 98.7 98.8 360 96.4 97.7 95.6 310 96.8 95.3 97.2
Cephalosporins 2nd G Cefoxitin 11954 5.1 7.2* 4.7 860 15.8 20.2* 14.4 781 19.0 23.1 17.3 489 26.8 33.9 24.4 170 97.6 98.8 96.6 353 64.0 74.6* 58.1 308 8.4 19.0* 5.7
Cefuroxime 11933 4.3 6.7* 3.8 863 9.6 12.9* 8.6 781 16.1 22.0* 13.8 481 25.4 32.5* 22.9 165 98.8 98.8 98.8 356 62.4 75* 55.3 317 10.1 24.2* 6.4
Cephalosporins 3rd G Cefodizime 8959 0.4 0.8 0.3 609 1.3 1.3* 1.3 595 2.4 4.2 1.6 320 4.1 3.8 4.1 311 7.7 6.4 8.8 253 8.7 13.5 6.1 269 0.0 0.0 0.0
Ceftazidime 11743 1.2 1.6 1.1 863 5.9 4.8 6.3 776 7.9 12.6* 6.0 487 10.3 12.1 9.6 436 4.1 1.9 6.1 347 13.8 17.6 11.7 310 1.0 1.6 0.8
Ceftibuten 12022 0.9 1.3 0.8 864 3.8 3.9 3.8 791 2.4 1.8 2.6 485 5.8 6.7 5.5 425 26.8 28.2 25.6 355 11.5 15.1* 9.6 313 0.0 0.0 0.0
Cephalosporins 4th Cefepime 11921 0.3 0.3 0.3 859 3.7 2.4 4.1 763 1.6 2.8 1.1 488 4.1 4.8 3.8 420 4.8 5.0 4.5 349 5.7 8.7* 4.0 314 0.0 0.0 0.0
Monobactams Aztreonam 11922 2.9 3.5 2.8 861 15.4 14.6 15.7 775 6.2 6.8 5.9 470 21.5 24.2 20.6 423 5.4 5.5 5.4 329 19.8 19.3 20.0 310 5.2 6.3 4.9
Nitrofurans Nitrofurantoin 11768 6.0 9.0* 5.4 863 95.1 95.7 95.0 768 32.8 39.5* 30.2 483 97.1 100.0* 96.1 347 39.5 51.6* 32.6 307 87.3 89.2 86.8
Penicillins Amoxicillin 11943 42.4 50.3* 40.8 863 47.7 55.3* 45.3 372 96.8 99.0 95.9 487 97.9 99.2 97.5 359 98.6 99.2 98.3 314 99.0 100.0 98.8
AMX-CLA 11879 7.5 10.3* 6.9 863 11.8 20.1* 9.2 316 81.6 85.1 80.3 486 32.9 41.9* 29.8 345 83.2 87.1 81.0 309 18.4 27.7* 16.0
Piperacillin 11749 19.5 24.0* 18.5 832 20.0 24.7 18.5 457 37.4 49.6* 33.4 418 24.2 24.1 24.2 335 34.9 45.8* 29.0 300 26.7 33.8 24.7
Pivmecillinam 11546 15.8 20.9* 14.7 812 37.7 44.7* 35.4 707 24.8 32.4* 21.5 450 59.1 71.9* 54.8 323 46.7 57.1* 41.2 285 24.2 32.8* 22.0
Quinolones Ciprofloxacin 11952 13.9 22.2* 12.2 865 21.3 35.1* 16.9 784 22.3 32.4* 18.3 484 25.0 36.4* 21.2 440 43.4 45.7 41.4 357 23.8 36.9* 16.3 312 18.3 27.7* 15.8
Lomefloxacin 10634 13.7 22.6* 11.9 765 21.8 33.0* 18.5 641 22.9 34.1* 18.8 420 25.2 38.8* 20.8 349 43.8 46.9 41.2 302 25.2 44.7* 15.1 272 18.8 28.3* 16.4
Norfloxacin 11893 14.2 22.8* 12.3 867 22.8 36.2* 18.6 779 21.7 31.3* 18.0 470 24.9 36.2* 21.2 437 44.9 48.1 42.0 355 26.5 44.2* 16.4 307 19.2 29.7* 16.5
Ofloxacin 11937 14.4 23.0* 12.6 860 22.9 35.9* 18.7 783 22.2 32.3* 18.2 483 26.1 38.2* 21.9 438 45.0 48.3 42.1 356 27.2 44.6* 17.3 310 19.4 29.7* 16.7
Sulfonamides SxT 11907 25.4 33.0* 23.8 831 41.5 55.0* 37.2 776 36.0 41.4 33.8 482 57.3 64.5 54.7 356 39.3 56.6* 29.5 303 23.1 30.3 21.1

AMX - CLA Amoxicillin-clavulanic acid, SxT Trimethoprim-Sulfamethoxazole, n total number of bacteria resistant to each antimicrobial, N: total number of bacteria tested against each antimicrobial; — Antimicrobial not tested, M male patient, F female patient, *statistically significant differences (p-value < 0.05) of antimicrobial resistance between female and male patients.

Linhares et al.

Linhares et al. BMC Infectious Diseases 2013 13:19   doi:10.1186/1471-2334-13-19

Open Data